Klaus Kleinfeld, chief executive officer Siemens AG and memb

GERMANY - APRIL 27: Klaus Kleinfeld, chief executive officer Siemens AG and member of the Bayer AG supervisory board, reacts prior to the Bayer annual general meeting in Cologne, Germany, on Friday, April 27, 2007. Bayer AG bought Schering last year for 17 billion euros ($23 billion) to gain Schering's Yasmin birth control pills and its Betaseron multiple sclerosis treatment. The company expanded to be able to compete with rivals like GlaxoSmithKline Plc and Novartis AG. (Photo by Wolfgang Von Brauchitsch/Bloomberg via Getty Images)
GERMANY - APRIL 27: Klaus Kleinfeld, chief executive officer Siemens AG and member of the Bayer AG supervisory board, reacts prior to the Bayer annual general meeting in Cologne, Germany, on Friday, April 27, 2007. Bayer AG bought Schering last year for 17 billion euros ($23 billion) to gain Schering's Yasmin birth control pills and its Betaseron multiple sclerosis treatment. The company expanded to be able to compete with rivals like GlaxoSmithKline Plc and Novartis AG. (Photo by Wolfgang Von Brauchitsch/Bloomberg via Getty Images)
Klaus Kleinfeld, chief executive officer Siemens AG and memb
ACHETER UNE LICENCE
Comment puis-je utiliser cette image ?
475,00 €
EUR

INFORMATIONS

Restrictions :
Contactez votre agence locale pour toute utilisation commerciale ou promotionnelle.For editorial use only. Additional clearance required for commercial or promotional use, contact your local office for assistance. Any commercial or promotional use of Bloomberg content requires Bloomberg’s prior written consent.
Crédits :
Bloomberg / Contributeur
Editorial - n° :
94611991
Collection :
Bloomberg
Date de création :
27 avril 2007
Date de chargement :
Type de licence :
Infos autorisations :
Autorisation non disponible. Plus d'infos
Source :
Bloomberg
Référence :
pdir0640\SHi_j0059.JPG